Christopher O. is a Principal Scientist at Capsida Biotherapeutics specializing in AAV-based gene therapy for CNS and cardiac indications. With a Ph. D. from the University of Rhode Island, he leads discovery and IND-enabling programs by integrating in vivo pharmacology, disease modeling, and next-generation viral vectors.
He was a featured speaker at the 5th Annual CNS Drug Delivery Summit, presenting new preclinical data on CNS-targeted capsids.
Read the full overview →
Experience
17 Years
Current Role
Principal Scientist
Location
Los Angeles, California, United States
Personality Overview
How Christopher shows up
ROI Driven
Objective Thinker
Negotiator
They don’t appreciate bells and whistles unless backed by data. They like to take decisions independently and do not seek others' support often. They prefer to analyze logically and value objective facts over emotions.
Priorities
Topics Christopher cares about
CNS Drug Delivery
Presented new data on CNS-targeted capsids and other preclinical studies at the 5th Annual CNS Drug Delivery Summit in late 2023.
AAV Gene Therapy
Leads discovery and early translational research for AAV-based gene therapy programs targeting central nervous system and cardiac diseases.
+4 more topicsLogin to view topics
Career
Work history
1-2024 - 11-2025
Principal Scientist
Capsida Biotherapeutics
1-2022 - 12-2023
Senior Scientist
Capsida Biotherapeutics
10-2020 - 1-2022
Scientist II
Capsida Biotherapeutics
8-2014 - 8-2020
Postdoctoral Scholar
David Geffen School of Medicine at UCLA
8-2010 - 8-2014
Graduate Research Assistant
University of Rhode Island
In the press
Media appearances
No media yetWe could not find public media appearances for this person.
Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.
More profiles
Discover additional public profiles from our index.